Hepatocellular carcinoma (HCC) is the principal primary liver tumor, representing the third largest cause of cancer‑associated death worldwide. The actual reference standard systemic treatment for advanced HCC is represented by sorafenib, a multi‑targeted orally active small‑molecule tyrosine kinase inhibitor. Sorafenib has exhibited a good general safety profile in multiple clinical trials. However, adverse drug‑associated events are common, occasionally severe, and special attention should be paid to cardiovascular adverse events, particularly in patients with risk factors or known heart disease. In the present study, the case of a patient with no known cardiovascular risk factors affected by highly enhancing advanced HCC in cirrhotic liver, who died during successful sorafenib monotherapy, is reported.
Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis / Calistri, Linda; Cordopatri, Cesare; Nardi, Cosimo; Gianni, Elena; Marra, Fabio; Colagrande, Stefano. - In: MOLECULAR AND CLINICAL ONCOLOGY. - ISSN 2049-9450. - ELETTRONICO. - 6:(2017), pp. 389-396. [10.3892/mco.2017.1132]
Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis
Calistri, Linda
;NARDI, COSIMO;MARRA, FABIO;COLAGRANDE, STEFANO
2017
Abstract
Hepatocellular carcinoma (HCC) is the principal primary liver tumor, representing the third largest cause of cancer‑associated death worldwide. The actual reference standard systemic treatment for advanced HCC is represented by sorafenib, a multi‑targeted orally active small‑molecule tyrosine kinase inhibitor. Sorafenib has exhibited a good general safety profile in multiple clinical trials. However, adverse drug‑associated events are common, occasionally severe, and special attention should be paid to cardiovascular adverse events, particularly in patients with risk factors or known heart disease. In the present study, the case of a patient with no known cardiovascular risk factors affected by highly enhancing advanced HCC in cirrhotic liver, who died during successful sorafenib monotherapy, is reported.File | Dimensione | Formato | |
---|---|---|---|
92) Mol Clinical Onco HCC in good response.pdf
Accesso chiuso
Descrizione: Articolo principale
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
663.22 kB
Formato
Adobe PDF
|
663.22 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.